Table 1.
Differential phosphorylation in PBMCs from MS patients relative to healthy controls
| Phosphorylation levels | ||||||
| Group | Stimulus | SNP: allele | MS | HCs | P | Adjusted P |
| MS | ||||||
| MKO3 | Baseline | rs666930: TT | 937 ± 480 | 463 ± 86 | 0.0011 | 0.004 |
| MP2K1 | vitD3 | rs35929052: CT | 0.44 ± 0.42 | −0.24 ± 0.2 | 1.32e-05 | 0.0016 |
| Baseline | rs666930: TT | 3,849 ± 1,794 | 2,041 ± 646 | 0.0019 | 0.04 | |
| RRMS | ||||||
| JUN | INS | rs11554159: GG | 0.12 ± 0.14 | −0.017 ± 0.1 | 0.00022 | 0.027 |
| MP2K1 | vitD3 | rs35929052: CT | 0.48 ± 0.47 | −0.24 ± 0.2 | 6.71e-05 | 0.008 |
The table shows the kinases that were more strongly phosphorylated in MS patients relative to the HCs, indicating the stimulus used in the in vitro assays and the susceptibility SNPs (Benjamin correction for multiple tests). The results are shown as the mean ± SD. Unstimulated basal phosphoprotein levels were compared using a Wilcoxon test, whereas a phosphorylation after stimulation was normalized and compared using a t test. INS, insulin; VitD3, vitamin D3.